ADMA Biologics Q2 2026: ASCENIV Drives 69% Gross Margin, Aggressive Buybacks Continue Amid Securities Lawsuit
ADMA sits 26% above its 52-week low of $7.21.
Summary
ADMA Biologics reported Q2 2026 net income of $37.8 million on revenue of $124.4 million, with ASCENIV growth offsetting BIVIGAM weakness. The company continued heavy share buybacks and disclosed a new securities class action lawsuit.
Key Events · Earnings and Guidance · ADMA
-
ASCENIV Revenue Jumps 23.5%
Driven by continued market acceptance and label expansion to pediatric patients, ASCENIV sales reached $102.9 million in Q2 2026, up from $83.3 million a year ago.
-
Gross Margin Expands to 69.4%
Gross profit of $86.3 million on revenue of $124.4 million yielded a 69.4% margin, up from 55.1% in Q2 2025, reflecting favorable product mix and yield enhancement benefits.
-
BIVIGAM Sales Plunge 48.5%
Aggressive competitive pricing in the standard immune globulin market pressured BIVIGAM revenue, which fell to $19.4 million from $37.7 million.
-
Aggressive Share Repurchases Continue
In H1 2026, the company spent $156.4 million on buybacks, including a $125 million accelerated share repurchase, reducing outstanding shares by over 12 million.
Analysis · ADMA · Life Sciences
A strong second quarter for ADMA Biologics was anchored by ASCENIV revenue, which surged 23.5% to $102.9 million, and gross margins that expanded to 69.4% from 55.1% a year ago, thanks to favorable product mix and yield enhancements. Offsetting this, BIVIGAM sales collapsed 48.5% under competitive pressure, and the company disclosed a new securities class action lawsuit filed in July. Meanwhile, $156.4 million was spent on share repurchases in the first half, including a $125 million accelerated share repurchase, reducing the share count by over 12 million shares. The combination of robust profitability, aggressive capital return, and emerging litigation risk makes this a pivotal update for investors.
At the time of this filing, ADMA was trading at $9.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $7.21 to $20.46. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.